Streamlining Pulmonology Claim Status Tracking for Enhanced Revenue Cycle Efficiency

Klivira's platform automates pulmonology claim status tracking, providing real-time visibility and proactive management for complex respiratory claims, from high-cost biologics to durable medical equipment.

For pulmonology practices, managing the lifecycle of claims for high-cost biologics, specialized therapies, and durable medical equipment presents unique challenges. Manual claim status checks consume significant staff time and often lead to lost revenue from aged or unaddressed denials. Klivira transforms this process by automating status inquiries and linking them directly to the initial prior authorization.

The Unique Demands of Pulmonology Claims

Pulmonology claims often involve high-cost, high-scrutiny services such as asthma biologics (e.g., omalizumab, mepolizumab, dupilumab, tezepelumab), IPF antifibrotics (e.g., pirfenidone, nintedanib), and essential durable medical equipment like home oxygen and BiPAP. These claims are frequently subject to complex payer policies, including step-therapy requirements and specific documentation thresholds (e.g., eosinophil counts for IL-5 targeting biologics), making their status particularly critical to track.

Common Claim Status Challenges in Pulmonology

Manual polling of payer portals or phone calls for status updates on high-volume biologic claims.
Difficulty interpreting payer-specific X12 277 status codes, leading to inconsistent follow-up.
Claims for home oxygen or BiPAP languishing in 'pending' status, risking timely-filing breaches.
Disconnection between initial prior authorization approval and the subsequent claim's status, obscuring discrepancies.
Overhead associated with reconciling X12 835 remittance advice against submitted pulmonology claims.

Klivira's Automated Pulmonology Claim Status Tracking

Klivira's platform provides automated claim status tracking tailored to the complexities of pulmonology. We leverage X12 277 polling on configurable schedules, ingesting X12 835 remittance data, and integrating with FHIR ClaimResponse for payers utilizing Da Vinci PAS workflows. This ensures comprehensive, real-time visibility into the status of every pulmonology claim, from submission through payment or denial.

Addressing Pulmonology-Specific Claim Delays and Denials

**Normalized Status Taxonomy**: Payer-specific status codes for asthma biologics or IPF antifibrotics are normalized into a uniform claim-state model, eliminating interpretation variability.
**PA-to-Claim Linkage**: Klivira maintains the critical link between the prior authorization for services like severe asthma maintenance therapies or lung transplant evaluations and the subsequent claim, flagging discrepancies.
**Stuck-Claim Escalation**: Claims for high-cost pulmonology procedures or DME that remain in 'pending' or 'review' status beyond configurable thresholds automatically trigger follow-up workflows.
**Proactive Denials Management**: Early identification of claims denied due to issues like unmet step-therapy for asthma biologics (e.g., requiring high-dose ICS-LABA trial per GINA/GOLD guidelines) or eosinophil-count thresholds not met, enables timely appeals.

Integration with Pulmonology Workflows and Guidelines

Klivira integrates seamlessly with existing EMR systems, embedding automated claim status updates directly into the pulmonology workflow. This ensures that prior authorization coordinators and revenue cycle teams have immediate access to claim status, informed by relevant clinical guidelines from bodies like ATS, GOLD for COPD, and GINA for asthma, without manual intervention. The system's ability to track and escalate claims helps prevent revenue loss from common denial reasons, such as insufficient conservative therapy for IPF antifibrotics.

Frequently asked questions

How does Klivira handle X12 277 claim status inquiries for pulmonology services?

Klivira automates X12 277 claim status polling to payers on configurable schedules. This includes specific logic for high-volume pulmonology claims like those for asthma biologics or home oxygen, ensuring timely updates without manual staff intervention. The system normalizes payer-specific responses into a consistent status taxonomy.

Can Klivira track the status of claims for specific asthma biologics like Dupixent or Nucala?

Yes, Klivira's platform is designed to track claims for all pulmonology-specific services, including high-cost asthma biologics such as omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab. Our system maintains the linkage between the initial prior authorization and the claim, providing detailed status updates and flagging any discrepancies.

What happens if a pulmonology claim, such as for home oxygen, gets stuck in 'pending' status?

Klivira's system includes robust 'stuck-claim escalation' rules. If a pulmonology claim, including those for home oxygen or BiPAP, remains in a 'pending' or 'review' status beyond a configurable threshold, the platform automatically triggers follow-up workflows, such as portal escalation alerts or prompts for payer outreach, to prevent timely-filing breaches.

How does Klivira link prior authorization to claim status for pulmonology procedures?

Klivira maintains a direct linkage between the prior authorization obtained for a pulmonology service (e.g., lung transplant evaluation, severe asthma maintenance therapy) and its subsequent claim. This connection allows the system to surface any discrepancies between the authorized service and the billed claim, aiding in compliance and reducing denials related to authorization mismatches.

Does Klivira integrate with FHIR-based claim status for pulmonology payers?

Yes, for payers that support FHIR-based claim flows, Klivira consumes ClaimResponse resources via the Da Vinci PAS umbrella. This allows for a modern, standardized approach to obtaining and processing claim status information for pulmonology services, complementing our robust X12 277 and 835 ingestion capabilities.